A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Trial Identifier: D967JC00002
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited
Start Date: December 2020
Primary Completion Date: August 2023
Study Completion Date: December 2025
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU East Melbourne, AU, 3002
AU Westmead, AU, 2145
BE Edegem, BE, 2650
BE Leuven, BE, 3000
BE Ottignies, BE, 1340
BR Goiania, BR, 74605-070
BR Porto Alegre, BR, 90035-003
BR Porto Alegre, BR, 90110-270
BR Sao Paulo, BR, 04543-000
BR São Paulo, BR, 03102-002
CA, BC Kelowna, BC, CA, V1Y 5L3
CA, QC Quebec, QC, CA, G1J 1Z4
FR Villejuif Cedex, FR, 94805
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 03080
KR Seoul, KR, 06351
MX Monterrey, MX, 64710
RU Moscow, RU, 143442
RU Moscow, RU, 115478
RU Saint Petersburg, RU, 199226
TW Kaohsiung, TW, 82445
TW Taichung, TW, 40443
TW Taipei, TW, 235
TW Taipei, TW, 11217
TW Taipei, TW, 100
TW Taipei, TW, 114
TW Taoyuan, TW, 333
US, NC Chapel Hill, NC, US, 27514
US, NY Commack, NY, US, 11725
US, NY New York, NY, US, 10065
US, NY New York, NY, US, 10029
US, NY Uniondale, NY, US, 11553
US, NY West Harrison, NY, US, 10604
US, TN Chattanooga, TN, US, 37404
US, TN Germantown, TN, US, 38138
US, TX Fort Worth, TX, US, 76104